Robert F Hobbs
Overview
Explore the profile of Robert F Hobbs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhatia R, George J, Siu C, Lee E, Redmond K, Baker B, et al.
Neurosurg Pract
. 2025 Feb;
5(4):e00117.
PMID: 39959539
Background And Objectives: In patients treated with stereotactic radiosurgery (SRS) for brain metastases, follow-up imaging demonstrating progression may result from treatment effect/radionecrosis (RN) or tumor progression. We report long-term outcomes...
2.
Stabinska J, Piccolo J, Chhabra A, Liatsou I, Gabrielson K, Li Z, et al.
Magn Reson Med
. 2025 Jan;
PMID: 39846230
Purpose: We hypothesized that radiation-induced tubulointerstitial changes in the kidney can be assessed using MRI-based T relaxation time measurements. Methods: We performed MRI, histology, and serum biochemistry in two mouse...
3.
Kiess A, ODonoghue J, Uribe C, Bodei L, Hobbs R, Hesterman J, et al.
J Clin Oncol
. 2024 Mar;
42(15):1734-1737.
PMID: 38484205
No abstract available.
4.
Sharma A, Gupta K, Mishra A, Lofland G, Marsh I, Kumar D, et al.
Adv Sci (Weinh)
. 2024 Feb;
11(16):e2308617.
PMID: 38421139
The limited availability of molecularly targeted low-molecular-weight imaging agents for monitoring multiple myeloma (MM)-targeted therapies has been a significant challenge in the field. In response, a first-in-class peptide-based radiotracer, [Ga]Ga-AJ206,...
5.
Josefsson A, Cortez A, Yu J, Majumdar S, Bhise A, Hobbs R, et al.
Nucl Med Biol
. 2024 Feb;
128-129:108880.
PMID: 38330637
Patients with HER2-positive and triple negative breast cancer (TNBC) are associated with increased risk to develop metastatic disease including reoccurring disease that is resistant to standard and targeted therapies. The...
6.
Benabdallah N, Lu P, Abou D, Zhang H, Ulmert D, Hobbs R, et al.
J Nucl Med
. 2023 Dec;
65(2):245-251.
PMID: 38124163
α-particle emitters are emerging as a potent modality for disseminated cancer therapy because of their high linear energy transfer and localized absorbed dose profile. Despite great interest and pharmaceutical development,...
7.
Kayal G, Barbosa N, Marin C, Ferrer L, Fragoso-Negrin J, Grosev D, et al.
J Nucl Med
. 2023 Oct;
65(1):125-131.
PMID: 37884334
Implementation of radiopharmaceutical therapy dosimetry varies depending on the clinical application, dosimetry protocol, software, and ultimately the operator. Assessing clinical dosimetry accuracy and precision is therefore a challenging task. This...
8.
Busse N, Al-Ghazi M, Abi-Jaoudeh N, Alvarez D, Ayan A, Chen E, et al.
J Appl Clin Med Phys
. 2023 Oct;
25(2):e14157.
PMID: 37820316
Radioembolization using Yttrium-90 ( Y) microspheres is widely used to treat primary and metastatic liver tumors. The present work provides minimum practice guidelines for establishing and supporting such a program....
9.
Boinapally S, Alati S, Jiang Z, Yan Y, Lisok A, Singh R, et al.
Molecules
. 2023 Aug;
28(16).
PMID: 37630410
Prostate-specific membrane antigen (PSMA)-based low-molecular-weight agents using beta(β)-particle-emitting radiopharmaceuticals is a new treatment paradigm for patients with metastatic castration-resistant prostate cancer. Although results have been encouraging, there is a need...
10.
Katugampola S, Hobbs R, Howell R
Med Phys
. 2023 Aug;
51(1):637-649.
PMID: 37558637
Background: Predicting biological responses to mixed radiation types is of considerable importance when combining radiation therapies that use multiple radiation types and delivery regimens. These may include the use of...